Monitor the AASLD conference for any incremental data readouts from the posters, but the primary binary catalyst remains the NATiV3 Phase 3 topline results expected in Q4 2026.
Price Chart
Executive Summary
Inventiva announced the presentation of three scientific abstracts at the upcoming AASLD The Liver Meeting 2026 (November 5-9), showcasing preclinical and Phase 2b data on lanifibranor's mechanism in MASH. The abstracts provide further biological rationale for its pan-PPAR approach but do not disclose new clinical efficacy or safety data. The key catalyst remains the Phase 3 NATiV3 topline results expected in Q4 2026.
Key Facts
- Three abstracts accepted for poster presentation at AASLD The Liver Meeting 2026 (Nov 5-9, Denver).
- Abstracts cover preclinical data on pan-PPAR activation across hepatic cell populations, Phase 2b results on liver sinusoidal endothelial cell improvements, and cfDNA epigenetic analysis in MASLD patients.
- Phase 3 NATiV3 trial topline results expected in Q4 2026.
- Lanifibranor has FDA Breakthrough Therapy and Fast Track designation for MASH.
Financial Impact
No financial figures disclosed; routine scientific conference presentation with no new clinical data or financial guidance.
Risk Factors
- NATiV3 trial failure or mixed results would be a severe negative catalyst for this pre-revenue biotech.
- Going concern risk highlighted in forward-looking statements regarding ability to obtain adequate financing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006471 |
| Document: f6k_100626.htm | 0001171843-26-006471 |
| Document: 0001171843-26-006471-index-headers.html | 0001171843-26-006471 |
| Document: 0001171843-26-006471-index.html | 0001171843-26-006471 |
| Document: 0001171843-26-006471.txt | 0001171843-26-006471 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $3.77 | awaiting T+20 | — | $3.68 (−2.25%) |
Oct 6, 2026 21d ago | 6-K | $3.37 | awaiting T+20 | — | $3.68 (+9.51%) |
Sep 28, 2026 29d ago | 6-K | $3.53 $3.66 | ▲ +3.68% | ▲ +3.71% | $3.68 (+4.39%) |
Sep 3, 2026 7w ago | 6-K | $4.84 $3.56 | ▼ −26.45% | ▼ −25.26% | $3.68 (−23.86%) |
Jul 6, 2026 16w ago | 6-K | $3.90 $4.48 | ▲ +14.87% | ▲ +15.44% | $3.68 (−5.51%) |
Jun 12, 2026 19w ago | 6-K | $3.76 $4.30 | ▲ +14.36% | ▲ +15.11% | $3.68 (−1.99%) |
Jun 12, 2026 19w ago | 6-K | $3.85 $4.30 | ▲ +11.69% | ▲ +9.91% | $3.68 (−4.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers